|
US3980781A
(en)
*
|
1966-03-31 |
1976-09-14 |
Imperial Chemical Industries Limited |
Fungicidal composition and method containing 2-amino-pyrimidines
|
|
GB1143167A
(en)
*
|
1967-01-25 |
1969-02-19 |
Ucb Sa |
Derivatives of pyrimidine
|
|
GB1369379A
(en)
*
|
1972-04-07 |
1974-10-09 |
Science Union & Cie |
Benzodioxole derivatives and processes for preparing them
|
|
US3988457A
(en)
*
|
1974-02-07 |
1976-10-26 |
Smithkline Corporation |
Novel compounds and compositions for treating Parkinson's disease
|
|
US3919230A
(en)
*
|
1974-02-07 |
1975-11-11 |
Smithkline Corp |
{62 -Naphthylmethyl piperazinyl derivatives
|
|
US3960863A
(en)
*
|
1974-06-25 |
1976-06-01 |
Sankyo Company Limited |
Pyrido[1,2-a]pyrimidinone derivatives
|
|
US4166852A
(en)
*
|
1974-08-09 |
1979-09-04 |
Produits Chimiques Ugine Kuhlmann |
Piperazino-pyrimidines and their use as spasmolytic agents
|
|
OA06083A
(fr)
*
|
1977-11-09 |
1981-06-30 |
Science Union & Cie Ste Franca |
Nouvelles pipérazines disubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant.
|
|
FR2519986A1
(fr)
*
|
1982-01-21 |
1983-07-22 |
Adir |
Nouveaux derives de benzodioxine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
|
|
FR2539990A1
(fr)
*
|
1983-01-28 |
1984-08-03 |
Sanofi Sa |
Composition pharmaceutique a action psychotrope dopaminergique contenant une 2-piperazinopyrimidine
|
|
US4605655A
(en)
*
|
1984-03-06 |
1986-08-12 |
Bristol-Myers Company |
Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
|
|
US4980350A
(en)
*
|
1988-02-25 |
1990-12-25 |
Merck & Co., Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
EP0330263A1
(en)
*
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
US4994460A
(en)
*
|
1989-06-01 |
1991-02-19 |
Bristol-Myers Squibb Co. |
Agents for treatment of brain ischemia
|
|
US5859246A
(en)
|
1997-01-30 |
1999-01-12 |
Neurogen Corporation |
1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
|
|
EP1032559B1
(en)
*
|
1997-09-29 |
2006-11-29 |
Aventis Pharmaceuticals Inc. |
Aminoalkylphenol derivatives for treating depression and memory dysfunction
|
|
US6825198B2
(en)
*
|
2001-06-21 |
2004-11-30 |
Pfizer Inc |
5-HT receptor ligands and uses thereof
|
|
CN1681495B
(zh)
|
2002-08-19 |
2010-05-12 |
辉瑞产品公司 |
用于治疗过度增生性疾病的组合物
|
|
CN1910159A
(zh)
*
|
2004-01-16 |
2007-02-07 |
诺瓦提斯公司 |
2,4－二氨基嘧啶和它们用于诱导心肌发生的用途
|
|
US7241891B2
(en)
*
|
2004-03-29 |
2007-07-10 |
Chung-Shan Institute Of Science & Technology |
Method for the purification of Piribedil
|
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
JP5498168B2
(ja)
|
2006-12-01 |
2014-05-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
|
|
CN101735201B
(zh)
*
|
2009-12-17 |
2012-05-30 |
宁夏康亚药业有限公司 |
一种吡贝地尔的制备方法
|
|
CN101830891A
(zh)
*
|
2010-05-18 |
2010-09-15 |
沈阳药科大学 |
一种吡贝地尔的制备方法
|
|
EP2986599A1
(en)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
|
JP6563017B2
(ja)
|
2014-08-28 |
2019-08-21 |
エースニューロン・ソシエテ・アノニム |
グリコシダーゼ阻害剤
|
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
|
WO2018153508A2
(en)
|
2017-02-24 |
2018-08-30 |
Asceneuron S.A. |
Sulfoximine glycosidase inhibitors
|
|
EP3419971B1
(en)
|
2016-02-25 |
2022-04-20 |
Asceneuron SA |
Glycosidase inhibitors
|
|
KR20180132060A
(ko)
|
2016-02-25 |
2018-12-11 |
아셰뉴론 에스아 |
피페라진 유도체의 산 부가 염
|
|
MX2018010191A
(es)
|
2016-02-25 |
2019-05-20 |
Asceneuron S A |
Inhibidores de glucosidasa.
|
|
US11261183B2
(en)
|
2016-02-25 |
2022-03-01 |
Asceneuron Sa |
Sulfoximine glycosidase inhibitors
|
|
CN106432212B
(zh)
*
|
2016-09-21 |
2019-01-11 |
苏州弘森药业股份有限公司 |
一种合成吡贝地尔的方法
|
|
CN107163032A
(zh)
*
|
2017-06-19 |
2017-09-15 |
太仓卡斯特姆新材料有限公司 |
一种高收率的吡贝地尔制备方法
|
|
CN107266429A
(zh)
*
|
2017-06-19 |
2017-10-20 |
太仓大唐化纤厂 |
一种高品质的吡贝地尔制备方法
|
|
CN107216318A
(zh)
*
|
2017-06-19 |
2017-09-29 |
太仓弘杉环保科技有限公司 |
一种吡贝地尔制备方法
|
|
CN107417674B
(zh)
*
|
2017-06-26 |
2020-12-29 |
苏州弘森药业股份有限公司 |
一种吡贝地尔的提纯方法
|
|
EP3672958B1
(en)
|
2017-08-24 |
2023-08-02 |
Asceneuron SA |
Annulated glycosidase inhibitors
|
|
EP3672959A1
(en)
|
2017-08-24 |
2020-07-01 |
Asceneuron SA |
Linear glycosidase inhibitors
|
|
RU2737721C2
(ru)
*
|
2017-12-15 |
2020-12-02 |
Алексей Георгиевич Александров |
Способ получения фармацевтической субстанции на основе пирибедила
|
|
WO2020039029A1
(en)
|
2018-08-22 |
2020-02-27 |
Asceneuron S. A. |
Spiro compounds as glycosidase inhibitors
|
|
WO2020039028A1
(en)
|
2018-08-22 |
2020-02-27 |
Asceneuron S. A. |
Tetrahydro-benzoazepine glycosidase inhibitors
|
|
US12016852B2
(en)
|
2018-08-22 |
2024-06-25 |
Asceneuron Sa |
Pyrrolidine glycosidase inhibitors
|
|
BR112021013807A2
(pt)
|
2019-01-18 |
2021-11-30 |
Astrazeneca Ab |
Inibidores de pcsk9 e seus métodos de uso
|
|
WO2020169804A1
(en)
|
2019-02-22 |
2020-08-27 |
Asceneuron Sa |
Fused glycosidase inhibitors
|